Coil reactor to introduce gas into flow chemical reaction on demand

We use cookies to enhance your experience.By continuing to browse this site you agree to our use of cookies.More information.
Uniqsis’s Gas Addition Module II (GAM II) is a coiled tube reactor that introduces gas “on demand” into reactions carried out under flow-through conditions by diffusion through gas-permeable membrane tubes.
With GAM II – your gas and liquid phases are never in direct contact with each other.As the gas dissolved in the flowing liquid phase is consumed, more gas diffuses rapidly through the gas permeable membrane tube to replace it.For chemists looking to perform efficient carbonylation or hydrogenation reactions – the novel design of the GAM II ensures that the flowing liquid phase is free of any undissolved air bubbles, providing greater stability, consistent flow rates and repeatable dwell time.
Available in 2 different versions – GAM II can be cooled or heated like a more traditional coil reactor.To ensure the most efficient heat transfer, the standard reactor outer tube can be made of 316L stainless steel.Alternatively, a thick-walled PTFE version of the GAM II provides improved chemical compatibility and visualization of reaction mixtures through opaque tube walls.Based on the standard Uniqsis coil reactor mandrel, the GAM II coil reactor is fully compatible with its full line of high performance flow chemistry systems and other reactor modules.
Uniqsis Ltd. (12 January 2022).Coil reactors are capable of introducing gases into flow chemical reactions on demand.News – Medical.Retrieved 11 May 2022 from
Uniqsis Ltd. “Coil reactors enable on-demand introduction of gases into flow chemical reactions”.News – Medical.May 11, 2022..
Uniqsis Ltd. “Coil reactors enable on-demand introduction of gases into flow chemical reactions”.News – Medical. 11 May 2022).
Uniqsis Ltd. 2022. Coil reactors introduce gas on demand into flow chemistry reactions.News-Medical, accessed May 11, 2022, aspx.
In this interview, News-Medical talks to Dr Ron Daniels about his work at the UK Sepsis Trust and the impact of antimicrobial resistance on sepsis.
In this interview, we talk to Michelle Egger, CEO and co-founder of BIOMILQ, about their breakthrough breast biotechnology.
In this interview, we interview Professor Joseph Powell about his latest research investigating the use of immune “fingerprints” to treat autoimmune diseases.
News-Medical.Net provides this medical information service in accordance with these terms and conditions.Please note that the medical information on this website is intended to support and not replace the patient-physician/physician relationship and the medical advice they may provide.

Post time: May-12-2022